BRAF and skin neoplasm: Treatment with BRAF inhibitors dabrafenib and vemurafenib can be associated with the abnormal skin growth, forming papilloma, keratoacanthoma, nevi, or even skin cancers such as squamous cell carcinoma and melanoma [99,153].